Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
European Journal of Haematology|April 21, 2023
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT studyNico Gagelmann, Dirk-Jan Eikema, Linda Koster, et al.
Experimental Hematology|March 31, 2004
Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choiceEliane Gluckman, Vanderson Rocha, William Arcese, et al.
Bone Marrow Transplantation|February 2, 2021
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMTGiorgia Battipaglia, Katya Mauff, Lotus Wendel, et al.
Blood|August 16, 2003
Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysisGerard Michel, Vanderson Rocha, Sylvie Chevret, et al.
Bone Marrow Transplantation|May 12, 2021
Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working PartyPatrick J Hayden, Dirk-Jan Eikema, Liesbeth C de Wreede, et al.
Bone Marrow Transplantation|January 30, 2021
Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWP-EBMTSimone Cesaro, Gloria Tridello, Nina Simone Knelange, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 4, 2012
Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant researchLeena V Maramattom, Parameswaran N Hari, Linda J Burns, et al.
The Lancet. Oncology|October 3, 2015
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trialAlessandro Rambaldi, Anna Grassi, Arianna Masciulli, et al.
Blood|August 10, 2019
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemiaAdriano Venditti, Alfonso Piciocchi, Anna Candoni, et al.
Transplantation and Cellular Therapy|May 9, 2021
Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei TrapiantiAlessandra Picardi, Nicoletta Sacchi, Valeria Miotti, et al.
Pageof 14